Rotational stability, centration, and patient satisfaction with the Clareon Panoptix Toric intraocular lens
Nuria Garzón1, Javier García-Bella2, Pedro Arriola-Villalobos2
1Faculty of Optics and Optometry. Complutense University Of Madrid, Madrid, Spain.
Purpose:
To evaluate the rotational stability, decentration, visual outcomes, and patient satisfaction after bilateral implantation of the trifocal toric intraocular lens (IOL), Clareon PanOptix Toric (Alcon, Fort Worth, TX, USA).
Setting:
San Carlos Hospital, Madrid, Spain.
Design:
Prospective, single-center, observational, non-comparative.
Methods:
Patients aged 50 years or older suitable for cataract surgery without comorbidities and with regular corneal astigmatism >1.50D were bilaterally implanted with the Clareon PanOptix Toric IOL and followed up for 3-months. Outcomes measured included IOL displacement and rotation, quantified by the PIOLET software. Additionally, refraction and uncorrected visual acuity (UDVA) at far (4 m) were measured, along with corrected visual acuities, monocular and binocular, at far (CDVA), intermediate (DCIVA), and near (DCNVA) distances.
Results:
A total of 80 eyes from 40 patients were included in this study. At 3 months, the mean rotation was 1.04 ± 0.97 degrees, and the mean displacement was 0.19 ± 0.36 mm along the X -axis and 0.19 ± 0.25 mm along the Y -axis. The postoperative spherical equivalent was -0.09 ± 0.35 D. Binocularly, the mean visual acuities were CDVA, -0.03 ± 0.05 logMAR; DCIVA, 0.07 ± 0.08 logMAR; and DCNVA, 0.09 ± 0.07 logMAR. Regarding satisfaction, 97% of patients indicated they were either very satisfied or fairly satisfied.
Conclusion:
The bilateral implantation of the Clareon PanOptix Toric IOL demonstrates excellent rotational stability, minimal decentration, and effective astigmatism correction. It provides strong visual acuity outcomes and high patient satisfaction, making it a viable option for patients seeking spectacle independence.
Related Concept Videos
Focusing of Light in the Eye
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Properties of Enantiomers and Optical Activity


